The Group's principal activity is to develop therapeutic products for the treatment of severe diseases including autoimmune disorders and cancer. The products include Pexelizumab, Eculizumab, UniGraft-SCI and UniGraft-PD. Pexelizumab, is an antibody fragment being developed in collaboration with Procter & Gamble Pharmaceuticals. Through its subsidiaries, the Group is engaged in the discovery and development of a portfolio of additional antibody therapeutics targeting severe unmet medical needs.
Alacra Alerts:
Receive alerts on the latest reports on Alexion Pharmaceuticals, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
